Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection

  • days left to enroll
  • participants needed
  • sponsor
    Mahidol University
Updated on 27 January 2021


This is an open label randomised controlled study of oral ivermectin (600 mcg/kg/d* 3 day) versus combined of hydroxychloroquine plus darunavir/ ritonavir for 5 days treatment among asymptomatic carrier of SAR-CoV2 adult Thai population. Both study treatment regimens will have oral zinc sulfate combination treatment ( 200mg. twice daily). Outcomes include safety and duration of detectable of SAR-CoV2 in nasopharyngeal/ throat (NP) swab by polymerase chain reaction amplification (PCR) after treatment. 40-50 patients in each treatment arm is planned, with an interim analysis when approximately 50% of cases is enrolled.


  • Study procedure will be carried out after informed consent is obtained.
    • Baseline physical exam and laboratory investigations will be performed.
    • Eligible patients will be randomized to one of the two treatment arms.
    • Symptoms and signs will be monitored daily.
    • NP swab will be done at day5-7, and prior to discharge.
    • Complete blood counts, blood chemistries, electrocardiography will be performed for adverse event monitoring within 5 days after end of study drugs' administration.
    • Patients will be discharged at 2- 4 weeks after hospitalization, according to PCR results.
    • There will be 1-2 follow up visit at out patient clinic for NP swab (patients with +ve last NP swab before discharge), and blood tests.
    • Additional 5-8 ml. of EDTA blood will be taken at baseline and weekly for antibody detection.
    • Interim analysis of both safety and efficacy will be performed when approximately 50% of enrollment is achieved.
    • Intention to treat analysis is planned at the completion of enrollment.

Condition Subclinical infection, asymptomatic infections, asymptomatic infection, SARS-CoV2 Infection, SARS-CoV2 Infection
Treatment Ivermectin Pill, Combined ART/hydroxychloroquine
Clinical Study IdentifierNCT04435587
SponsorMahidol University
Last Modified on27 January 2021


Yes No Not Sure

Inclusion Criteria

SAR-CoV2 detected by PCR from NP swab
Asymptomatic or upper respiratory symptoms such as runny noses
No history of fever or oral Temp <37.8 degree celsius
informed consent obtained

Exclusion Criteria

Fever or respiratory rate >24/minute or oxygen saturation at room air< 94%
Any serious co-morbidity such as chronic lung disease, chronic kidney disease, cardiovascular diseases, arrythmia, diabetes mellitus with HbA1C > 8%, chronic liver disease, lymphocyte count <1,000cell/cu.mm
History of ivermectin or any of the study drug allergy
Concomitant medication with potential drug interaction with any of the study drugs such as alfuzosin, colchicine, ergot derivatives, cisapride, simvastatin and rifampicin
Pregnant or lactating woman
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note